for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding Ltd.

RO.S

Latest Trade

295.40CHF

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

231.20

 - 

296.60

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
295.40
Open
--
Volume
--
3M AVG Volume
37.63
Today's High
--
Today's Low
--
52 Week High
296.60
52 Week Low
231.20
Shares Out (MIL)
856.06
Market Cap (MIL)
255,925.10
Forward P/E
15.23
Dividend (Yield %)
2.79

Next Event

Roche Holding AG at Jefferies London Healthcare Conference

Latest Developments

More

Roche Presents Results Of Phase II Gazyva Study

Dicerna & Roche To Develop DCR-HBVS For Treatment Of Chronic Hepatitis B Virus Infection

Roche: FDA Accepts Genentech's Biologics License Application For Satralizumab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding Ltd.

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry

Major Drugs

Contact Info

Grenzacherstr. 124

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Fritz Gerber

Honorary Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

50.6K

2017

53.3K

2018

56.8K

2019(E)

62.0K
EPS (CHF)

2017

15.340

2019(E)

17.089
Price To Earnings (TTM)
21.82
Price To Sales (TTM)
4.32
Price To Book (MRQ)
9.09
Price To Cash Flow (TTM)
15.88
Total Debt To Equity (MRQ)
69.75
LT Debt To Equity (MRQ)
54.88
Return on Investment (TTM)
23.03
Return on Equity (TTM)
15.43

Latest News

Latest News

BRIEF-Roche Presents Results Of Phase II Gazyva Study

* ANNOUNCES DATA FROM PHASE II NOBILITY STUDY, INVESTIGATING THE SAFETY AND EFFICACY OF GAZYVA

BRIEF-Roche: FDA Accepts Genentech's Biologics License Application For Satralizumab

* FDA ACCEPTS GENENTECH'S BIOLOGICS LICENSE APPLICATION FOR SATRALIZUMAB FOR NEUROMYELITIS OPTICA SPECTRUM DISORDE Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-UK competition watchdog launches Roche-Spark inquiry

* UK'S CMA - CONSIDERING WHETHER ROCHE-SPARK DEAL MAY RESULT IN LESSENING OF COMPETITION WITHIN ANY MARKET OR MARKETS IN UK FOR GOODS OR SERVICES

BRIEF-Roche Holding: FDA Approval For Xofluza

* ROCHE ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR PEOPLE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS

AstraZeneca breast cancer treatment gets FDA priority review

AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct competition with bigger rival Roche Holding AG.

BRIEF-Roche CEO does not expect U.S. to slap tariffs on European drugs

* CEO SAYS BELIEVES CONCERNS, REPORTS ABOUT U.S. TARIFFS IMPACT ON SWISS DRUGMAKERS 'BASED ON WRONG FACTS'

BRIEF-Roche Says Phase 3 Study Shows Mabthera/Rituxan Superior To Mycophenolate Mofetil In Patients With Pemphigus Vulgaris

* PHASE III PEMPHIX STUDY SHOWS ROCHE’S MABTHERA/RITUXAN (RITUXIMAB) SUPERIOR TO MYCOPHENOLATE MOFETIL IN PATIENTS WITH PEMPHIGUS VULGARIS

BRIEF-Roche Company Chugai Says Obtained Approval For Additional Indication And Formulation For Tecentriq In Pd-L1-Positive Triple Negative Breast Cancer In Japan

* COMPANY CHUGAI SAYS OBTAINED APPROVAL FOR ADDITIONAL INDICATION AND FORMULATION FOR TECENTRIQ IN PD-L1-POSITIVE TRIPLE NEGATIVE BREAST CANCER IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Roche Holding Reports Analysis Of Ocrevus Phase IIIb Study

* POST-HOC ANALYSIS FROM A PHASE III OPEN-LABEL EXTENSION STUDY SHOWED A 42 PERCENT REDUCTION IN RISK OF PPMS PATIENTS NEEDING A WHEELCHAIR AFTER 6.5 YEARS OF OCREVUS TREATMENT COMPARED WITH PATIENTS WHO STARTED OCREVUS AFTER DOUBLE-BLIND PERIOD

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding <ROG.S> and Spark Therapeutics <ONCE.O> announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

BRIEF-Roche Presents Positive Study Results For One-Dose Xofluza In Children With Flu

* ROCHE PRESENTS POSITIVE PHASE III STUDY RESULTS FOR ONE-DOSE XOFLUZA IN CHILDREN WITH FLU

BRIEF-Enable Injections Enters Into Partnership With Genentech

* ENABLE INJECTIONS ENTERS INTO STRATEGIC PARTNERSHIP WITH GENENTECH, A MEMBER OF THE ROCHE GROUP

Roche taps Lilly executive Garraway as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche taps Eli Lilly executive as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

Roche prices personalized cancer treatment at about $204,560 annually

Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

BRIEF-Roche Announces Monthly and Yearly Rozlytrek Treatment Costs In U.S.

* ROCHE - MONTHLY COST OF ROZLYTREK FOR ADULTS WITH ROS1-POSITIVE METASTATIC NSCLC & FOR ADULTS WITH NTRK FUSION-POSITIVE SOLID TUMOURS IS ABOUT $17,050

BRIEF-Roche Wins U.S. FDA Approval For Rozlytrek Cancer Treatment

* FDA APPROVES ROCHE’S ROZLYTREKTM (ENTRECTINIB) FOR PEOPLE WITH ROS1-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER AND NTRK GENE FUSION-POSITIVE SOLID TUMOURS

Roche's personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, which targets tumors with specific genetic mutations, irrespective of where in the body the disease started, the agency said on Thursday.

Roche's personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, the agency said on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up